micro-community-banner
 
  • Saved

1yr
Myocardial Inflammation in Heart Failure With Reduced and Preserved Ejection Fraction

Myocardial Inflammation in Heart Failure With Reduced and Preserved Ejection Fraction

Source : https://pubmed.ncbi.nlm.nih.gov/38843295/

Heart failure (HF) is characterized by a progressive decline in cardiac function and represents one of the largest health burdens worldwide. Clinically, 2 major types of HF are distinguished based...

To regulate immune responses in heart failure (HF) through blocking the proinflammatory cytokine TNF-α failed despite promising preclinical data and success in autoimmune diseases. Recent discoveries, such as the production of the cytokine Oncostatin M in HF patients, which makes them unresponsive to anti-TNF-α treatment, highlight the need...

  • Saved

1yr
Integration mapping of cardiac fibroblast single-cell transcriptomes elucidates cellular principles of fibrosis in diverse pathologies

Integration mapping of cardiac fibroblast single-cell transcriptomes elucidates cellular principles of fibrosis in diverse pathologies

Source : https://pubmed.ncbi.nlm.nih.gov/38905342/

Single-cell technology has allowed researchers to probe tissue complexity and dynamics at unprecedented depth in health and disease. However, the generation of high-dimensionality single-cell atlases and virtual three-dimensional tissues requires...

Single-cell technology has allowed researchers to probe tissue complexity and dynamics at unprecedented depth in health and disease. However, the generation of high-dimensionality single-cell atlases and virtual three-dimensional tissues requires integrated reference maps that harmonize disparate experimental designs, analytical pipelines,...

  • Saved

1yr
Loop diuretic discontinuation in chronic heart failure patients: A retrospective study

Loop diuretic discontinuation in chronic heart failure patients: A retrospective study

Source : https://pubmed.ncbi.nlm.nih.gov/38906521/

In our cohort, loop diuretic discontinuation was possible and safe in a large proportion of patients. The results should be interpreted with caution and cannot be extrapolated to a broader...

In our cohort, loop diuretic discontinuation was possible and safe in a large proportion of patients. The results should be interpreted with caution and cannot be extrapolated to a broader population of HF patients.

  • Saved

1yr
Guideline-directed medical therapy for heart failure

Heart failure (HF) with preserved ejection fraction (HFpEF), which is defined as HF with left ventricular ejection fraction (LVEF) of 50% or more, accounts for more than 50% of HF cases in the United States, and its incidence continues to rise. Historically, treatment for HFpEF was limited to the management of comorbidities, but newer clinical data have established sodium-glucose transport protein 2 (SGLT2) inhibitors as an effective treatment option. The American College of Cardiology (ACC) now recommends initiating SGLT2 inhibitor therapy in all patients with HFpEF.

Inhibitors of SGLT2 also play a key role in treating HF with reduced ejection fraction (HFrEF), in which LVEF is 40% or less. In its 2024 update, the ACC recommends starting treatment for symptomatic HFrEF with the “4 pillars”:

  1. Angiotensin receptor-neprilysin inhibitor
  2. Beta blocker
  3. Mineralocorticoid antagonist
  4. SGLT2 inhibitor

In your patients, how do you manage HF, regardless of ejection fraction?

  • 1yr
    I am still a little old fashioned and like to use inexpensive medications at time of first diagnosis. Patients may rebel if hit with too many medications at once Show More
  • 1yr
    I tend to use the same medications regardless of Lvef. Which medication I start with depends on how congested they are and what their blood pressure is. Show More

Show More Comments

  • Saved

1yr

High Throughput Plasma Proteomics and Risk of Heart Failure and Frailty in Late Life

Source : https://jamanetwork.com/journals/jamacardiology/article-abstract/2819212?resultClick=24

These findings provide insight into the shared pathobiology of heart failure and frailty in late life and suggest potential molecular pathways that can be targeted by interventions to mitigate the burden of both conditions.